Researchers identified a new cellular protection pathway that targets a common vulnerability in several pandemic viruses, including Ebola and SARS-CoV-2. The study found that the MHC class II transactivator CIITA induces resistance by activating CD74, which disrupts viral entry into cells.
The National Institute of Allergy and Infectious Diseases has awarded BRI a five-year, $8 million grant to collaborate with UW Medicine and SCRI on immune system responses to allergens in the lungs. This study aims to inform new treatments for allergies and asthma.
A clinical trial has found that regular peanut consumption begun in early infancy and continued until age 5 reduced the rate of peanut allergy in at-risk infants by 80% compared to non-peanut-consumers. After a one-year period of peanut avoidance, only 4.8% of original peanut consumers were found to be allergic.
The T1DAL study found that alefacept treatment preserved beta cell function in 30% of participants with new-onset type 1 diabetes. Alefacept also reduced insulin dose requirements and major hypoglycemic events compared to the placebo group.
Erik Wambre, PhD, at Benaroya Research Institute will study T cells causing peanut allergy and analyze genes to neutralize these cells. The goal is to develop new approaches for diagnosis and treatment of food allergies.
Researchers at Benaroya Research Institute have discovered that chitin, previously thought to be absent in vertebrates, is endogenously produced in fishes and amphibians. This finding challenges longstanding biological assumptions and opens up new avenues for biomedical applications.
A new study found that consuming peanut-containing snacks from infancy can prevent peanut allergy in high-risk infants. In contrast, avoiding peanuts led to a higher risk of developing the allergy by age 5. The findings suggest a shift in advice for parents and healthcare providers to promote early consumption of allergenic foods.
A recent study published in Diabetes Care found that approximately one-third of people with type 1 diabetes produce insulin, as measured by C-peptide, even up to 40 years after diagnosis. This challenges the long-held assumption that these patients lose all ability to produce insulin, highlighting potential implications for clinical pr...
Scientists aim to understand immune system factors that influence insulin production in people with type 1 diabetes. They hope to develop biomarkers and a drug combination to help people live with fewer complications and increased ability to manage their disease.
The institute aims to discover a biomarker that predicts the onset of allergy and leads to novel vaccine approaches, aiming to develop a simple blood test to predict likelihood of resolution or development of an allergy.
Researchers at Benaroya Research Institute used cutting-edge tetramer technology to find T cells driving rheumatoid arthritis. The study demonstrates that these cells have unique markers and change over time in patients with RA.
Researchers analyzed T cell receptor sequences to understand immune system reconstitution following high-dose immunosuppression. CD4+ and CD8+ lymphocytes exhibit different reconstitution patterns, with dominant clones expanded or undetectable at 12 months post-transplant.
A phase II study found that alefacept treatment significantly reduced insulin use and hypoglycemic events in newly diagnosed type 1 diabetics. The therapy targeted memory T-cells, preserving regulatory T-cells.
Researchers aim to understand factors that make immune cells target the spinal cord and brain, leading to multiple sclerosis (MS). The study will determine the function of specific T cells, how they are generated, and how they can be regulated in model systems of MS and humans.
A phase II study tested thymoglobulin, an antithymocyte globulin treatment, in new-onset type 1 diabetic patients. While most younger patients showed decline in beta cell function, older patients experienced little change. The study did not meet its primary endpoint and may have identified biomarkers for safety and efficacy.
A recent clinical trial found that patients with new-onset type 1 diabetes treated with teplizumab exhibit greater preservation of C-peptide, a biomarker of islet cell function. Further analysis identified a discrete subset of treatment responders who demonstrated especially robust responses.
The ITN has made its clinical trial data and analysis code publicly available through the TrialShare portal, allowing researchers to access raw study data, confirm published conclusions, and perform interactive analyses. This move aims to enhance scientific collaboration and speed up the sharing of research results.
Researchers demonstrate that a single course of rituximab therapy is as effective as the current standard of care regimen in patients with ANCA-associated Vasculitis. The RAVE study shows that a short course of rituximab can induce and maintain remission, providing an alternative to long-term cyclophosphamide treatment.
Scientists at Benaroya Research Institute and Baylor Institute for Immunology Research report a comparative study of molecular immune responses to influenza and pneumococcal vaccines. The study utilized cutting-edge web technology to improve data dissemination, allowing researchers to investigate the primary data from a web portal.
The coelacanth genome provides valuable clues for biologists studying the evolution of vertebrates, with key genes involved in immunity, nitrogen excretion, and limb development implicated in evolutionary transitions. The study offers a comprehensive look at the coelacanth's place in our evolutionary history.
The Benaroya Research Institute has established a T1D Exchange Biobank Operations Center with a $4.4 million grant from The Leona M. and Harry B. Helmsley Charitable Trust. This center will coordinate clinical study proposals and sample requests, facilitating research with thousands of participants.
Researchers at Benaroya Research Institute found that IL-6 signaling pathway proteins may serve as novel biomarkers for MS disease activity and a potential therapeutic target. The study discovered that T cells in patients with active MS were more sensitive to IL-6, which could lead to new therapies targeting the IL-6 pathway.
Benaroya Research Institute (BRI) has received a $100,000 grant from the Bill & Melinda Gates Foundation to develop rapid malaria vaccines using synthetic minigene libraries. This innovative approach aims to identify protective target antigens in a fraction of the time required by conventional technologies.
Researchers from Benaroya Research Institute, Seattle Children's Research Institute, and University of Virginia are joining forces to study the genetic causes of Type 1 diabetes. The study aims to identify immunologic pathways involved in the disease, which can be targeted for diagnosis and therapy.
Researchers at Benaroya Research Institute will receive $4.7 million in grants to study immune function and develop new therapies for autoimmunity prevention. The goals include understanding how the immune system becomes unbalanced in individuals with autoimmune diseases.
A study on sea lampreys reveals that they undergo programmed genome rearrangement and gene loss during early development, sealing away potentially deleterious genes. This discovery builds on previous research and may provide insights into how vertebrate genomes remain stable, with potential implications for human health.
A six-week experimental allergy treatment has relieved hay fever symptoms for at least two years in a clinical trial. The novel DNA-based drug AIC blocks the seasonal rise in ragweed-specific IgE and reduces IL-4, hinting at successful immune system reprogramming.
A multicenter clinical trial confirmed the Edmonton Protocol's ability to safely promote long-term stabilization of blood sugar levels in 'brittle' diabetes patients, with some achieving insulin independence. Investigators also reported improved measures of blood glucose control and reversal of hypoglycemic unawareness.
The study confirmed that islet transplantation works for patients with serious and unstable type 1 diabetes, allowing them to be free from daily insulin injections for up to one year. Few treatment-related complications were noted, with minor side effects such as mouth ulcers and diarrhea.
The ITN multicenter islet transplant trial has confirmed that the procedure can be of great benefit to patients with serious and unstable type 1 diabetes. However, differences in success rates between individual clinical centers were noted, highlighting the need for expertise in islet preparation procedures.